Democritus University of Thrace (DUTH)
Προγνωστικοί μοριακοί βιολογικοί δείκτες του καρκινώματος της ουροδόχου κύστης
Abstract
dc:descriptionAim: The diagnosis and follow-up of patients with urinary bladder tumors classically become by cystoscopy and urine cytology. In the aim of early diagnosis and/or relapse of disease, and improvement of the overall survival many studies referring to circulating tumor-markers are ongoing. Material-Methods: Patients with histologically confirmed transitional cancer of urinary bladder were eligible. Patients with other histological type (squamous cell, small-cell, etc), or other malignancy, or patients with presence of chronic urinary infection (prostatitis, cystitis, urinary TBC), or with presence of lithiasis were excluded. A total of 142 patients and 33 healthy controls entered this study. Fifty-six patients had local disease (T1-4N0M0, clinical stages I, II, III), and 86 had metastatic disease (TanyN1-3M0-1 or in relapse after previous surgery and/or radiotherapy). The following parameters were studied: Serum levels of metalloproteinase (MMP)-2, MMP-9, Tissue Inhibitor of Metalolproteinase (TIMP)-2, MMP-2/TIMP-2 ratio, CYFRA 21-1, CEA, Ca 125, Ca 19-9, β-HCG, AFP, and urine levels of NMP-22 and EGF. Serum or urine values of the above parameters were correlated with tumor size, tumor differentiation, clinical stage, and overall survival. In the group of patients with metastatic disease who were included for chemotherapy treatment, the correlation of the above parameters with treatment response was estimated. Results: In the group of patients with local disease, the cystoscopy and the urine cytology were found positive for 87.5% and 80.4% of patients respectively. Positive correlation between abnormal NMP-22 values and bladder tumor presence was found; on the contrary no correlation was established between abnormal EGF values and local disease. Patients with metastatic disease compared with those with local disease showed a statistical increase of all serum markers. Serum levels of MMP-2, MMP-9, TIMP-2, MMP2/TIMP2 ratio and CYFRA 21-1 had statistically significant difference among groups of local disease, metastatic disease and healthy controls. Specifically, in the group of patients with metastatic disease MMP-2 and CYFRA 21-1 showed significant differences between patients with lymphnode and soft tissue metastases. During chemotherapy period, MMP-2, MMP-9, MMP2/TIMP2 ratio, CYFRA 21-1 and βHCG were proved sensitive markers of treatment response. No correlation was established between value of the above serum parameters and tumor differentiation. Patients with local disease and high levels of serum MMP-9 showed poor survival; in the goup of metastatic disease, normal values of CYFRA 21-1 and βHCG were accompanied with statistically improved survival. Conclusions: Serum MMP-2, MMP-9, MMP-2/TIMP-2 ratio, CYFRA 21-1, and bHCG were found to be reliable markers of staging and follow-up of patients with bladder cancer. NMP-22 compared with EGF showed better correlation with presence of bladder tumor ³T 1.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2003
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Andreadis, Charalambos
- Ανδρεάδης, Χαράλαμπος
Subjects
dc:subject × 17- Καρκίνος ουροδόχου κύστης
- Μεταλλοπρωτεϊνάσες
- Κυτοκερατίνη 19
- Αναστολείς μεταλλοπρωτεϊνασών
- Επιδερμικός αυξητικός παράγων (EGF)
- Καρκινικοί δείκτες
- Urinary bladder cancer
- Metalloproteinases
- Cytokeratin-19
- Tissue inhibitors metalloproteinases (TIMPs)
- Epidermal growth factor (EGF)
- NMP-22
- Tumor markers
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/17465